Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,103 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00101231 | Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | terminated | Phase 1 | 88 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer | terminated | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 |
| clinicaltrials |
| NCT01463410 | Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler | terminated | — | 264 | Skyline Diagnostics BVINDUSTRY | 4 | May 29, 2013 | clinicaltrials |
| NCT00066417 | Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia | terminated | Phase 2 | 51 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | May 1, 2013 | clinicaltrials |
| NCT00393380 | Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor | terminated | Phase 2 | 13 | The Emmes Company, LLCINDUSTRY | 1 | Apr 29, 2013 | clinicaltrials |
| NCT00899951 | Studying Fentanyl in Patients With Cancer | terminated | — | 2 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 18, 2013 | clinicaltrials |
| NCT00658411 | Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation | terminated | N/A | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 9, 2013 | clinicaltrials |
| NCT00006220 | Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy | terminated | Phase 1 / Phase 2 | 5 | Washington University School of MedicineOTHER | 1 | Feb 6, 2013 | clinicaltrials |
| NCT00089388 | Cilengitide in Treating Patients With Acute Myeloid Leukemia | terminated | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00096148 | Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00023920 | Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia | terminated | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00042796 | Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | terminated | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT01265199 | Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML) | terminated | Phase 1 | 29 | Ascenta TherapeuticsINDUSTRY | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00101088 | Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | terminated | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT00125606 | Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide | terminated | Phase 3 | 30 | University Hospital MuensterOTHER | 1 | Dec 18, 2012 | clinicaltrials |
| NCT00005641 | Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | terminated | Phase 2 | — | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 11, 2012 | clinicaltrials |
| NCT00005852 | Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant | terminated | Phase 2 | — | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Dec 11, 2012 | clinicaltrials |
| NCT00790855 | Bendamustine in Acute Leukemia and MDS | terminated | Phase 1 / Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 4, 2012 | clinicaltrials |
| NCT00069992 | Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML(MPDMDSBMT) | terminated | Phase 2 | 7 | Baylor College of MedicineOTHER | 1 | Oct 10, 2012 | clinicaltrials |
| NCT00062231 | Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer | terminated | N/A | 351 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Sep 24, 2012 | clinicaltrials |
| NCT00676728 | A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome | terminated | Phase 1 | 10 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 1 | Sep 14, 2012 | clinicaltrials |
| NCT00038818 | CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation | terminated | N/A | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 23, 2012 | clinicaltrials |
| NCT00113321 | Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00480987 | Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) | terminated | Phase 1 / Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00443300 | Effectiveness of Protected Environment Rooms for AML and MDS | terminated | — | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00513305 | Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia | terminated | Phase 3 | 67 | CephalonINDUSTRY | 2 | Aug 1, 2012 | clinicaltrials |
| NCT01645124 | Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)(CYTO-PV) | terminated | Phase 3 | 365 | Consorzio Mario Negri SudOTHER | 1 | Jul 20, 2012 | clinicaltrials |
| NCT00893997 | PR1 Vaccination in Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2012 | clinicaltrials |
| NCT00253552 | G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders | terminated | N/A | 4 | OHSU Knight Cancer InstituteOTHER | 1 | May 28, 2012 | clinicaltrials |
| NCT00827099 | Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer | terminated | Phase 2 | 5 | Northside Hospital, Inc.OTHER | 1 | Mar 23, 2012 | clinicaltrials |
| NCT01066468 | Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. | terminated | Phase 1 | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 13, 2012 | clinicaltrials |
| NCT01546337 | Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic Syndrome(EPO) | terminated | — | 30 | Rennes University HospitalOTHER | 1 | Mar 7, 2012 | clinicaltrials |
| NCT00074750 | Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) | terminated | Phase 1 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 22, 2012 | clinicaltrials |
| NCT00446303 | A Phase II Study of Maintenance With Azacitidine in MDS Patients | terminated | Phase 2 | 39 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Jan 19, 2012 | clinicaltrials |
| NCT00245128 | Imatinib Mesylate in Treating Patients With Myelofibrosis | terminated | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 13, 2012 | clinicaltrials |
| NCT00895297 | Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia(Dasatinib) | terminated | Phase 2 | 50 | European Society for Blood and Marrow TransplantationNETWORK | 4 | Dec 7, 2011 | clinicaltrials |
| NCT00519090 | Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)(ENEST) | terminated | Phase 3 | 6 | Novartis PharmaceuticalsINDUSTRY | 10 | Nov 7, 2011 | clinicaltrials |
| NCT00918931 | Obatoclax for Systemic Mastocytosis | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 4, 2011 | clinicaltrials |
| NCT00430443 | Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML | terminated | Phase 1 | 3 | Callisto PharmaceuticalsINDUSTRY | 1 | Aug 31, 2011 | clinicaltrials |
| NCT00915811 | Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin(FB-ATG) | terminated | Phase 2 | 20 | King's College Hospital NHS TrustOTHER | 1 | Aug 17, 2011 | clinicaltrials |
| NCT00839059 | Lenalidomide In Patients With Acute Myeloid Leukemia | terminated | Phase 1 | 14 | University of UlmOTHER | 1 | Jul 29, 2011 | clinicaltrials |
| NCT00381693 | Azacitidine in Treating Patients With Myelofibrosis | terminated | Phase 2 | 10 | Mayo ClinicOTHER | 1 | Apr 21, 2011 | clinicaltrials |
| NCT00531310 | Reduced Intensity AlloSCT in(CML) With Persistent Disease(CML) | terminated | Phase 2 | 5 | Columbia UniversityOTHER | 1 | Apr 14, 2011 | clinicaltrials |
| NCT00522574 | A Safety Study of XL019 in Adults With Myelofibrosis | terminated | Phase 1 | 100 | ExelixisINDUSTRY | 1 | Apr 5, 2011 | clinicaltrials |
| NCT00813501 | Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases | terminated | — | 60 | City of Hope Medical CenterOTHER | 1 | Mar 7, 2011 | clinicaltrials |
| NCT01034410 | A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 2 | 90 | Antisoma ResearchINDUSTRY | 4 | Feb 2, 2011 | clinicaltrials |
| NCT00486265 | Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML) | terminated | Phase 1 | 47 | AstraZenecaINDUSTRY | 2 | Dec 21, 2010 | clinicaltrials |
| NCT00279773 | Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia | terminated | Phase 1 | 34 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 30, 2010 | clinicaltrials |
| NCT00322673 | Study of XL999 in Patients With Acute Myeloid Leukemia (AML) | terminated | Phase 2 | 14 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 22, 2010 | clinicaltrials |
| NCT00004058 | 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder | terminated | Phase 1 | — | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jan 26, 2010 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2013source: clinicaltrials